Risk Factors in Schizophrenia Relapse

​Relapse in schizophrenia is most strongly associated with modifiable factors such as antipsychotic non‑adherence, persistent substance use, high family criticism or expressed emotion, psychosocial stress, and prior relapse history. Demographic, medical, and lifestyle variables (e.g., comorbidities, unemployment, low social support, sleep and activity patterns) also contribute to risk in specific populations. 
 
Medication non‑adherence increases relapse risk in schizophrenia by allowing underlying pathophysiology to re‑emerge, worsening symptoms, and destabilizing psychosocial functioning over time. Clinically, this translates into more frequent psychotic exacerbations, longer time to remission, and higher rates of emergency care and rehospitalization. Across cohorts, the most consistent single predictor is poor or irregular antipsychotic adherence, which increases relapse risk several‑fold and explains a large share of post‑discharge relapses. Previous relapse and recent hospitalization are also powerful predictors, with prior episodes and care escalations signalling increased vulnerability to another break. 
 
Antipsychotics work largely by maintaining a relatively steady level of dopamine D2 receptor blockade; when doses are missed or stopped, receptor occupancy falls below the threshold needed to suppress positive symptoms. Intermittent or abrupt discontinuation can therefore trigger rapid re‑emergence of delusions, hallucinations, and agitation, especially in the first few years after onset when illness is most active. Repeated cycles of stopping and restarting medication may also contribute to treatment failure, with patients responding more slowly or incompletely to the same drug on re‑exposure. This pattern is associated with more severe symptom trajectories and higher cumulative relapse risk.
 
Non‑adherence is consistently linked to markedly higher relapse and readmission rates: odds ratios around 3–5 for relapse and rehospitalization compared with adherent patients are commonly reported. Each relapse episode often brings incomplete symptom recovery, greater negative symptoms, and cognitive or functional decline, making subsequent decompensations more likely. Because relapses frequently require urgent care, non‑adherence also lengthens hospital stays and delays remission, increasing disability and caregiver burden. Over the long term, this pattern is associated with poorer quality of life and increased mortality risk, including from suicide and comorbid medical illness.
 
Non‑adherence rarely occurs in isolation; it is strongly associated with poor insight, negative attitudes to medication, substance use, and minimal family or social support. Substance use (especially cannabis and stimulants) both undermines adherence and independently increases relapse risk, creating a mutually reinforcing cycle. Practical barriers such as side effects, financial constraints, and complex regimens also drive non‑adherence and thereby relapse. Addressing these contributors (e.g., side‑effect management, psychoeducation, simplification of dosing, long‑acting injectables, and substance‑use treatment) is therefore central to relapse prevention strategies.
 
Persistent substance use (e.g., alcohol, cannabis, stimulants) independently elevates relapse risk, partly by worsening symptoms and undermining adherence. Residual positive or affective symptoms and comorbid medical or psychiatric conditions, such as diabetes or depression, further increase the likelihood of decompensation.
 
High expressed emotion (EE) in relatives, characterised by critical comments, hostility, or emotional overinvolvement, is a robust predictor of relapse, with markedly higher rates in high‑EE versus low‑EE households. Caregiver criticism specifically, even outside full EE constructs, has been shown to roughly double relapse risk in early‑phase psychosis.
 
Low social support, unemployment, impaired activities of daily living, and financial strain (e.g., limited insurance coverage) are associated with more frequent relapse after discharge. Stressful or negative life events and high environmental stress load can precipitate relapse, especially when combined with other vulnerabilities.
 
In early‑phase psychosis, meta‑analytic work highlights four independent predictors: medication non‑adherence, persistent substance use, caregiver criticism, and poorer premorbid adjustment, with non‑adherence increasing risk roughly fourfold. Limited access to second‑generation agents, self‑directed dose reduction, and skipping doses are notable relapse drivers in first‑episode samples.
 
In elderly patients on maintenance treatment, irregular medication, low exercise frequency, inadequate family care, negative life events, and shortened sleep duration have emerged as independent relapse predictors. These data suggest that behavioural and caregiving factors may be particularly salient in late‑life schizophrenia during the maintenance phase.
 
These domains are useful for structured risk assessment and for targeting relapse‑prevention interventions (e.g., adherence work, substance use treatment, family interventions, and stress management).
 
References
Abdellati, K. E., Picker, L.D. & Morrens, M. (2020, October 9). Antipsychotic Treatment Failure: A Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis. Frontiers in Neuroscience.
 
Amaresha, A.C. & Venkatasubramanian, G. (2012, Jan-Mar). 34(1):12-20. Expressed Emotion in Schizophrenia: An Overview. Indian Journal of Psychological Medicine.
 
Guo, J., Lv, X., Liu, Y., Kong, L.L., Qu, H.Y. & Yue, W.H. (2023, May 15). Influencing Factors of Medication Adherence in Schizophrenia Patients: A Meta-Analysis. Schizophrenia.
 
Mi, W.F., Chen, X.M., Fan, T.T., Tabarak, S., Xiao, J.B., et al. (2020, September 11). Identifying Modifiable Risk Factors for Relapse in Patients with Schizophrenia in China. Frontiers in Psychiatry.
 
Rivelli, A., Fitzpatrick, V., Nelson, M., Laubmeier, K., Zeni, C. & Mylavarapu, S. (2024, February 29). 10(1):28. Real-World Predictors of Relapse in Patients with Schizophrenia and Schizoaffective Disorder in a Large Health System. Schizophrenia.
 
Tibbo, P., Malla, A., Manchanda, R., Williams, R. & Joober, R. (2014, December). 59(12):655-658. Relapse Risk Assessment in Early Psychosis: The Search for a Reliable and Valid Tool. Canadian Journal of Psychiatry.
 
Zu, B., Wang, T., Pan, C., Li, W., An, L. et al. (2025, April 21). 26(2):39866. Risk Factors for Relapse of Schizophrenia in Elderly During the Maintenance Phase: A Matched Case-Control Study. Alpha Psychiatry.